Identifying Allergic Drug Reactions Through Placebo-Controlled Graded Challenges

Melissa M. Iammatteo, Denisa E. Ferastraoaru, Rebecca Koransky, Santiago Alvarez-Arango, Niharika Thota, Ayobami Akenroye, Elina Jerschow

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Graded challenges are performed to exclude hypersensitivity reactions in patients with a low likelihood of drug allergy. Literature regarding optimal protocols with a defined number of steps and use of placebo is lacking. Objective: To identify allergic drug reactions (ADRs) through a 3-step protocol composed of placebo followed by a 2-step graded drug challenge. Methods: We performed a 5-year retrospective chart review of all patients with historical ADRs who underwent single-blind, placebo-controlled graded drug challenges between October 2010 and November 2015 at an outpatient drug allergy clinic. Patients' demographic characteristics and description of historical reaction were obtained. Outcomes of challenges to drug versus placebo were compared by drug class. Results: Two hundred twenty-nine patients underwent at least 1 single-blind placebo-controlled graded challenge. The most commonly challenged drug class was beta-lactams (70.8%) followed by nonsteroidal anti-inflammatory drugs (17.5%). The reaction rate to drug and placebo was similar during beta-lactam challenges (9.4% vs 8.2%; . P = .9) and during nonsteroidal anti-inflammatory drug challenges (14% vs 7%, . P = .5), respectively. Only 10 patients (4.4%) had objective findings during drug challenges. Patients who reacted to placebo before beta-lactam challenges had an increased number of drug allergies (4.3 ± 1.0) compared with nonreactors (2.4 ± 0.1) and to beta-lactam reactors (3.3 ± 0.7) (P = .002). All placebo reactors were female (20 of 183 vs 0 of 46 males; . P = .02). Conclusions: Two-step graded challenges are safe in appropriately selected patients with a low risk of reaction. Placebo should be considered to reduce false-positive results, especially in females and in patients with multiple drug allergies.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology: In Practice
DOIs
StateAccepted/In press - Jun 11 2016

Fingerprint

Hypersensitivity
Placebos
Pharmaceutical Preparations
Drug Hypersensitivity
beta-Lactams
Anti-Inflammatory Agents
Outpatients
Demography

Keywords

  • Adverse drug reaction
  • Drug allergy
  • Drug provocation test
  • Graded challenge
  • Hypersensitivity reaction
  • Placebo

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Identifying Allergic Drug Reactions Through Placebo-Controlled Graded Challenges. / Iammatteo, Melissa M.; Ferastraoaru, Denisa E.; Koransky, Rebecca; Alvarez-Arango, Santiago; Thota, Niharika; Akenroye, Ayobami; Jerschow, Elina.

In: Journal of Allergy and Clinical Immunology: In Practice, 11.06.2016.

Research output: Contribution to journalArticle

Iammatteo, Melissa M. ; Ferastraoaru, Denisa E. ; Koransky, Rebecca ; Alvarez-Arango, Santiago ; Thota, Niharika ; Akenroye, Ayobami ; Jerschow, Elina. / Identifying Allergic Drug Reactions Through Placebo-Controlled Graded Challenges. In: Journal of Allergy and Clinical Immunology: In Practice. 2016.
@article{29f34d2768824c10a98478d6d2dc84ae,
title = "Identifying Allergic Drug Reactions Through Placebo-Controlled Graded Challenges",
abstract = "Background: Graded challenges are performed to exclude hypersensitivity reactions in patients with a low likelihood of drug allergy. Literature regarding optimal protocols with a defined number of steps and use of placebo is lacking. Objective: To identify allergic drug reactions (ADRs) through a 3-step protocol composed of placebo followed by a 2-step graded drug challenge. Methods: We performed a 5-year retrospective chart review of all patients with historical ADRs who underwent single-blind, placebo-controlled graded drug challenges between October 2010 and November 2015 at an outpatient drug allergy clinic. Patients' demographic characteristics and description of historical reaction were obtained. Outcomes of challenges to drug versus placebo were compared by drug class. Results: Two hundred twenty-nine patients underwent at least 1 single-blind placebo-controlled graded challenge. The most commonly challenged drug class was beta-lactams (70.8{\%}) followed by nonsteroidal anti-inflammatory drugs (17.5{\%}). The reaction rate to drug and placebo was similar during beta-lactam challenges (9.4{\%} vs 8.2{\%}; . P = .9) and during nonsteroidal anti-inflammatory drug challenges (14{\%} vs 7{\%}, . P = .5), respectively. Only 10 patients (4.4{\%}) had objective findings during drug challenges. Patients who reacted to placebo before beta-lactam challenges had an increased number of drug allergies (4.3 ± 1.0) compared with nonreactors (2.4 ± 0.1) and to beta-lactam reactors (3.3 ± 0.7) (P = .002). All placebo reactors were female (20 of 183 vs 0 of 46 males; . P = .02). Conclusions: Two-step graded challenges are safe in appropriately selected patients with a low risk of reaction. Placebo should be considered to reduce false-positive results, especially in females and in patients with multiple drug allergies.",
keywords = "Adverse drug reaction, Drug allergy, Drug provocation test, Graded challenge, Hypersensitivity reaction, Placebo",
author = "Iammatteo, {Melissa M.} and Ferastraoaru, {Denisa E.} and Rebecca Koransky and Santiago Alvarez-Arango and Niharika Thota and Ayobami Akenroye and Elina Jerschow",
year = "2016",
month = "6",
day = "11",
doi = "10.1016/j.jaip.2016.09.041",
language = "English (US)",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",

}

TY - JOUR

T1 - Identifying Allergic Drug Reactions Through Placebo-Controlled Graded Challenges

AU - Iammatteo, Melissa M.

AU - Ferastraoaru, Denisa E.

AU - Koransky, Rebecca

AU - Alvarez-Arango, Santiago

AU - Thota, Niharika

AU - Akenroye, Ayobami

AU - Jerschow, Elina

PY - 2016/6/11

Y1 - 2016/6/11

N2 - Background: Graded challenges are performed to exclude hypersensitivity reactions in patients with a low likelihood of drug allergy. Literature regarding optimal protocols with a defined number of steps and use of placebo is lacking. Objective: To identify allergic drug reactions (ADRs) through a 3-step protocol composed of placebo followed by a 2-step graded drug challenge. Methods: We performed a 5-year retrospective chart review of all patients with historical ADRs who underwent single-blind, placebo-controlled graded drug challenges between October 2010 and November 2015 at an outpatient drug allergy clinic. Patients' demographic characteristics and description of historical reaction were obtained. Outcomes of challenges to drug versus placebo were compared by drug class. Results: Two hundred twenty-nine patients underwent at least 1 single-blind placebo-controlled graded challenge. The most commonly challenged drug class was beta-lactams (70.8%) followed by nonsteroidal anti-inflammatory drugs (17.5%). The reaction rate to drug and placebo was similar during beta-lactam challenges (9.4% vs 8.2%; . P = .9) and during nonsteroidal anti-inflammatory drug challenges (14% vs 7%, . P = .5), respectively. Only 10 patients (4.4%) had objective findings during drug challenges. Patients who reacted to placebo before beta-lactam challenges had an increased number of drug allergies (4.3 ± 1.0) compared with nonreactors (2.4 ± 0.1) and to beta-lactam reactors (3.3 ± 0.7) (P = .002). All placebo reactors were female (20 of 183 vs 0 of 46 males; . P = .02). Conclusions: Two-step graded challenges are safe in appropriately selected patients with a low risk of reaction. Placebo should be considered to reduce false-positive results, especially in females and in patients with multiple drug allergies.

AB - Background: Graded challenges are performed to exclude hypersensitivity reactions in patients with a low likelihood of drug allergy. Literature regarding optimal protocols with a defined number of steps and use of placebo is lacking. Objective: To identify allergic drug reactions (ADRs) through a 3-step protocol composed of placebo followed by a 2-step graded drug challenge. Methods: We performed a 5-year retrospective chart review of all patients with historical ADRs who underwent single-blind, placebo-controlled graded drug challenges between October 2010 and November 2015 at an outpatient drug allergy clinic. Patients' demographic characteristics and description of historical reaction were obtained. Outcomes of challenges to drug versus placebo were compared by drug class. Results: Two hundred twenty-nine patients underwent at least 1 single-blind placebo-controlled graded challenge. The most commonly challenged drug class was beta-lactams (70.8%) followed by nonsteroidal anti-inflammatory drugs (17.5%). The reaction rate to drug and placebo was similar during beta-lactam challenges (9.4% vs 8.2%; . P = .9) and during nonsteroidal anti-inflammatory drug challenges (14% vs 7%, . P = .5), respectively. Only 10 patients (4.4%) had objective findings during drug challenges. Patients who reacted to placebo before beta-lactam challenges had an increased number of drug allergies (4.3 ± 1.0) compared with nonreactors (2.4 ± 0.1) and to beta-lactam reactors (3.3 ± 0.7) (P = .002). All placebo reactors were female (20 of 183 vs 0 of 46 males; . P = .02). Conclusions: Two-step graded challenges are safe in appropriately selected patients with a low risk of reaction. Placebo should be considered to reduce false-positive results, especially in females and in patients with multiple drug allergies.

KW - Adverse drug reaction

KW - Drug allergy

KW - Drug provocation test

KW - Graded challenge

KW - Hypersensitivity reaction

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=85006977283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006977283&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2016.09.041

DO - 10.1016/j.jaip.2016.09.041

M3 - Article

C2 - 27888028

AN - SCOPUS:85006977283

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

ER -